Displaying 1 - 20 of 392 results
Released Company Title Industry Topic
23 May 2020
07:00 CEST
IPSEN Ipsen:New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence Pharmaceuticals Other subject
23 May 2020
07:00 CEST
IPSEN Ipsen : De nouvelles enquêtes montrent que plus de 80 % des patients atteints de spasticité et de dystonie cervicale traitée par toxine botulique de type A constatent une récurrence des symptômes invalidants Pharmaceuticals Other subject
19 May 2020
11:10 CEST
IPSEN Ipsen annonce la publication dans Advances in Therapy de la première comparaison indirecte ajustée par appariement entre Cabometyx® (cabozantinib) et le régorafénib dans le traitement du carcinome hépatocellulaire avancé Pharmaceuticals Other subject
19 May 2020
11:10 CEST
IPSEN Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy Pharmaceuticals Other subject
07 May 2020
18:45 CEST
IPSEN Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Pharmaceuticals Other subject
07 May 2020
18:45 CEST
IPSEN Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company Pharmaceuticals Other subject
07 May 2020
18:30 CEST
IPSEN Ipsen: Information Relating to the Combined Shareholders’ Meeting of 29 May 2020 Pharmaceuticals Other subject
07 May 2020
18:30 CEST
IPSEN IPSEN : INFORMATIONS CONCERNANT LA TENUE DE L’ASSEMBLEE GENERALE MIXTE DU 29 MAI 2020 Pharmaceuticals Other subject
04 May 2020
07:00 CEST
IPSEN Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program Pharmaceuticals Other subject
04 May 2020
07:00 CEST
IPSEN Ipsen, IRICoR et l’Université de Montréal concluent un accord avec option de licence pour un programme d’oncologie en phase de recherche Pharmaceuticals Other subject
22 Apr 2020
07:00 CEST
IPSEN Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact Pharmaceuticals Sales
22 Apr 2020
07:00 CEST
IPSEN Ipsen enregistre une solide croissance des ventes au premier trimestre 2020 avec un impact limité lié au COVID-19 Pharmaceuticals Sales
20 Apr 2020
14:13 CEST
IPSEN Ipsen annonce des résultats préliminaires positifs de l’étude pivotale de phase III CheckMate -9ER évaluant CABOMETYX® (cabozantinib) en combinaison avec Opdivo® (nivolumab) ... Pharmaceuticals Other subject
20 Apr 2020
14:13 CEST
IPSEN Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma Pharmaceuticals Other subject
16 Apr 2020
18:00 CEST
IPSEN Ipsen Publishes Its 2019 Universal Registration Document Pharmaceuticals Other subject
16 Apr 2020
18:00 CEST
IPSEN Ipsen publie son Document d’enregistrement universel 2019 Pharmaceuticals Other subject
14 Apr 2020
19:00 CEST
IPSEN Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company Pharmaceuticals Other subject
14 Apr 2020
19:00 CEST
IPSEN Ipsen : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Pharmaceuticals Other subject
01 Apr 2020
07:00 CEST
IPSEN Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 Pharmaceuticals Other subject
01 Apr 2020
07:00 CEST
IPSEN Ipsen donne deux millions d’euros à l’Institut Pasteur pour soutenir la recherche sur le COVID-19 Pharmaceuticals Other subject